Physician profile
Stephen Hakimi
NPI 1285686485
$15,159.41
in general payments reported to CMS, 2019-2025
27 companies · $2,333 in 2025
The $2,333 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,287 · 2020: $81.90 · 2021: $1,198 · 2022: $3,605 · 2023: $3,659 · 2024: $995 · 2025: $2,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,937 · Travel and Lodging: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,937.45 |
| Travel and Lodging | $1,049.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,970.58 | 2019-2021 | |
| Alcon Vision LLC | $2,923.22 | 2019-2025 | Air Optix, Dailies Aqua Comfort Plus, Total30 |
| Bausch & Lomb Americas INC. | $2,052.92 | 2022-2025 | Miebo, Infuse, Xiidra |
| Johnson & Johnson Vision Care, INC. | $1,761.78 | 2020-2023 | Acuvue |
| Sun Pharmaceutical Industries INC. | $1,067.05 | 2019-2025 | Cequa |
| Abbvie INC. | $570.71 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $566.10 | 2024-2025 | Xdemvy |
| Coopervision INC. | $480.40 | 2022-2025 | Myday Contact Lens, Misight Contact Lens, Biofinity Contact Lens |
| Allergan, INC. | $471.07 | 2019-2022 | |
| Dompe US, INC. | $278.56 | 2023-2025 | Oxervate |
| Glaukos Corporation | $247.01 | 2022-2025 | Photrexa Viscous and Photrexa |
| Kala Pharmaceuticals, INC. | $176.80 | 2021-2022 | |
| Sight Sciences, INC. | $166.62 | 2022-2023 | Tearcare System |
| Mallinckrodt Hospital Products INC. | $160.39 | 2021-2023 | Acthar |
| Harrow Eye, LLC | $157.39 | 2025 | Vevye |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $143.28 | 2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $140.27 | 2019 | |
| Oyster Point Pharma, INC. | $135.39 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Biotissue Holdings INC. | $122.87 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $121.86 | 2025 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $119.33 | 2023 | |
| Shire North American Group INC | $111.07 | 2019 | |
| Optos, INC. | $93.75 | 2021 | |
| Abb Con-Cise Optical Group LLC | $36.48 | 2022 | |
| Thea Pharma INC. | $35.95 | 2025 | Iyuzeh |
| Rxsight INC | $32.83 | 2022-2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Eyevance Pharmaceuticals LLC | $15.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hakimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.